Hints and tips:
...A person close to the company rejected that, pointing to key roles played by Mene Pangalos, head of biopharma R&D, Ruud Dobber, head of the biopharma business, and Pam Cheng, head of global operations and...
...The African Union will pay three times more for Russia’s Sputnik V jab than it is paying for the Oxford/AstraZeneca and Novavax vaccines, according to people familiar with the procurement process....
...When the dust settles, that may well be AstraZeneca....
...It needs more doses now — but we also need to be ready for the variants,” said Angela Hwang, president of global biopharma for Pfizer, whose vaccine developed with Germany’s BioNTech was the first to win...
...Other deals included Bristol-Myers-Squibb’s $74bn takeover of biotech group Celgene and Pfizer’s $11.4bn acquisition of Array BioPharma....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...Moderna believes it has cracked this problem, but there is one snag: another group, Arbutus Biopharma, says it holds the patents to the delivery technology....
...Guardant has also signed deals with other large drugmakers like Merck and AstraZeneca, which want to use the test in their clinical trials....
...Hypocrisy aside, European companies already have an array of weapons at their hands — supervisory boards, works councils, “stichtings”, anchor investors and dual-class share structures — to make bidders...
...While a transformative merger may not now happen, “there are several small to midsize biopharma companies that Pfizer could potentially target in the coming months”....
...The other, MEK162, was produced under licence from Array BioPharma, a small Colorado-based company....
...The same goes for Pfizer’s approach to AstraZeneca, revealed a few days after the swoop on Allergan....
...“In Europe, investors have not always had the patience to give biopharma companies the time they need to grow,” says Flemming Ornskov, Shire chief executive, pictured, urging investors to back the board’...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Francis Cuss, BMS chief scientific officer, said in a statement: “We have decided to shift R&D toward a more speciality biopharma model that focuses on the areas of significant unmet medical need, driving...
...One is that prices for lettings, as commonly advertised, tend not to include an array of charges such as performing credit checks, arranging the contract, or conducting inventory checks (a service that is...
...And this week we announced a major agreement with the V.A....
...AstraZeneca reported first-quarter earnings per share up 10 per cent to $2.23, despite a 3 per cent fall in sales to $8.3bn (£5bn) as the impact of generic competition on its key products intensified....
...Traders cited rumours of interest from financier Joao V Azevedo, who has close links with Portuguese starch maker Copam....
International Edition